NSO Group used another WhatsApp zero-day after being sued, court docs say
Israeli surveillance firm NSO Group reportedly used multiple zero-day exploits, including an unknown one named "Erised," that ...
Visual Studio Magazine4h
Simple k-NN Regression Using C#
Dr. James McCaffrey from Microsoft Research presents a complete end-to-end demonstration of k-nearest neighbors regression to ...
The Register on MSN8m
Letting chatbots run robots ends as badly as you'd expect
The first law, "A robot may not injure a human being or, through inaction, allow a human being to come to harm," while ...
Zawya16h
Infoblox threat Intel identifies new malicious DNS threat actors linked to domain hijacking
The result is a new, eye-opening report estimating that over 1 million registered domains could be vulnerable daily ...
Gene Editing Market to Hit USD 7.59 Billion by 2029 with 10.2% CAGR | MarketsandMarkets™
The global gene editing market is expected to reach USD 7.59 billion in 2029 from USD 4.66 billion in 2024, at a CAGR of 10.2 ...
eLife6h
Maf-family bZIP transcription factor NRL interacts with RNA-binding proteins and R-loops in retinal photoreceptors
Neurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, United States This important study employed multiple orthogonal techniques and ...
Le Lézard9h
U.S. Postal Service Provides Sneak Peek at 2025 Stamps
The U.S. Postal Service today announced many of the stamps it will release in 2025. "This early glimpse into our 2025 stamp ...
SUSE unveils major rebranding, and a new AI platform that protects your data
SUSE has been busy! The European Linux power wants you to know it's also a major cloud and open-source player in North ...
Scotiabank Sticks to Its Buy Rating for Rocket Pharmaceuticals (RCKT)
In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report), ...
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who discontinued NUC ...
4D Molecular Therapeutics, Inc.: 4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patien ...